Chemotherapy

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Target, History, Cervical cancer, HPV, Bleeding, Discovery, Oncology, Mall of America, Spotting, R, News, Medication, Menopause, Chemotherapy, Therapy, Pharmaceutical formulation, Research, Birth control, Pharmaceutical industry, Medical imaging, Oil, Surveying, Marketing, Phase II, Development

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Drugs In Development, 2022, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.
  • - The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Cytotoxic Drugs and HPAPI Manufacturing Market Research Report 2022 - Industry Trends and Global Forecasts to 2035 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Pharmaceutical, Molecule, Chemotherapy, Pharmacology, Control, Partnership, SWOT, Overalls, Occupational exposure limit, Type, Growth, Fine chemical, Risk management

"Cytotoxic Drugs and HPAPI Manufacturing Market 2022-2035" report features an extensive study of the current market landscape and future potential of the HPAPI and cytotoxic drug manufacturing market, over the next decade.

Key Points: 
  • "Cytotoxic Drugs and HPAPI Manufacturing Market 2022-2035" report features an extensive study of the current market landscape and future potential of the HPAPI and cytotoxic drug manufacturing market, over the next decade.
  • One of the key objectives of the report was to evaluate the current opportunity and the future growth potential of the HPAPI and cytotoxic drug manufacturing market over the coming years.
  • Elaborate profiles of prominent players offering contract manufacturing services for HPAPI and cytotoxic drugs, across North America, Europe and Asia-Pacific.
  • The chapter also highlights the key components of ADCs and the key challenges associated with the manufacturing of these products.

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Monday, October 24, 2022
Immunology, Tukey's test of additivity, American Association for Cancer Research, Therapy, Conference, CD2, Neoplasm, Patient, Cytokine release syndrome, Research, Treatment, AACR, American Association, Association, Safety, CD28, GLOBE, EVOLVE, TILS, Chemotherapy, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry, Vaccine, Immunotherapy

BRANFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy. The results were featured in a poster presentation (#B44) entitled, “EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Solid Tumors,” at the conference, which was held October 21-23, 2022, in Boston.

Key Points: 
  • The results were featured in a poster presentation (#B44) entitled, EVOLVE: a Novel Costimulatory T Cell Engager Platform Engineered for the Treatment of Solid Tumors, at the conference, which was held October 21-23, 2022, in Boston.
  • Most current immunotherapies rely on the presence of pre-existing tumor-reactive T cells, which are absent or at low levels in many tumors.
  • Moreover, they do not provide coordinated costimulatory receptor activation to overcome T cell dysfunction and drive more effective and durable anti-tumor responses.
  • I am encouraged by these data and the potential of EVOLVE to break the solid tumor barrier.

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio

Retrieved on: 
Tuesday, September 13, 2022
Intas Biopharmaceuticals, Malignancy, Incidence, Mesothelioma, Ageing, Pemetrexed, Chest pain, Blistering, FDA, Solution, NSCLC, Vomiting, Population, MPM, Product, Lung cancer, Patient, Accord, Cancer, Technology, Heart, Research, Nausea, Fatigue, Chemotherapy, Pharmaceutical industry

DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs. The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.

Key Points: 
  • DURHAM, N.C., Sept. 13, 2022 /PRNewswire/ --Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Injection (Solution) to its line of chemotherapy drugs.
  • The new drug is formulated as a single-dose vial in 25-mg/ml concentrate for solution for infusion.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.

Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio

Retrieved on: 
Friday, May 27, 2022
Chest pain, Company, History, Nausea, Pemetrexed, Intas Biopharmaceuticals, Patient, Solution, National library, NSCLC, Research, Accord, FDA, Chemotherapy, Food and Drug Administration, Injection, United States National Library of Medicine, Technology, Product, Vomiting, Eli Lilly, Heart, Malignancy, MPM, Blistering, Mesothelioma, Cancer, MedlinePlus, Fatigue, Pharmaceutical industry, Medical imaging

DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo.

Key Points: 
  • DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo.
  • Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.

Global Brain Tumor Drugs Market (2022 to 2031) - Featuring Pfizer, Shimadzu and Celgene Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 7, 2022
Health, Pharmaceutical, Benchmark, Neoplasm, Meningioma, Cisplatin, Glioblastoma, Radiation, Schwannoma, Temozolomide, Lists of diseases, Growth, Coronavirus, Patient, Chemotherapy, Glioma, Everolimus, Cancer, Prevalence, Brain, Medulloblastoma, Regeneration, National Brain Tumor Society, Life expectancy, Carmustine, Infection, PNET, Create, Astrocytoma, Anaplastic astrocytoma, Brain tumor, Marketing, Medical imaging, Oligodendroglioma, Bevacizumab

The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.

Key Points: 
  • The brain tumor drugs market consists of sales of drugs which are used to cure a mass growth of abnormal cells in the human brain.
  • The main types of drugs in brain tumor drugs are temozolomide, carmustine, cisplatin, bevacizumab, geftinib and erlotinib.
  • The major driving factor responsible for the growth of Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide.
  • Increasing use of targeted therapies is acting as a restraint on the Brain Tumor drugs market.

$3.25 Billion Worldwide Ovarian Cancer Drugs Industry 2022 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Monday, March 28, 2022
General Health, Pharmaceutical, Health, Benchmark, Alkylation, C1-inhibitor, PARP, American Cancer Society, API, III, Genentech, Growth, Coronavirus, Compliance, Ovary, Fibroadenoma, Chemotherapy, Research, Ovarian cancer, Woman, Neoplasm, Incidence, Cancer, Death, Roche, Industry, Paclitaxel, Carboplatin, Create, Efficiency, FDA, Patient, Marketing, Birth control, Pharmaceutical industry, Bevacizumab

The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor.

Key Points: 
  • The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor.
  • Ovarian cancer that began in the epithelial layer protecting the ovary is known as epithelial ovarian cancer.
  • The rising incidence of ovarian cancer is driving the ovarian cancer drugs market.
  • Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 16, 2022
Research, Breast cancer, EIF4A, ER, STRI, PD, G&A, RNA transfection, Pembrolizumab, U.S. Securities and Exchange Commission, PI3K, Cyclic permutation, DARPA, Board of directors, Private Securities Litigation Reform Act, ImmunoGen, Exercise, COVID-19, Administration, Therapy, Clinical trial, Cancer, Population, UCSF, Novartis, D&O, Survival, Research and development, D, MNK, EIF4E, Patient, Memory, Fulvestrant, Escape Room, Pfizer, Senior, LPC, Large-cell lung carcinoma, Security (finance), NASDAQ, Protein, HIV disease progression rates, SAN, Achievement, Effector, GLOBE, Expense, Receptor tyrosine kinase, PD-L1, 4F, Safety, AKT, Chemotherapy, KRAS, Degenerative disease, R, Stri Parva, Pharmaceutical industry, Vaccine, KICKSTART, Income, NSCLC

This cohort will enroll approximately 60 patients, randomized 1:1 to initiate therapy with tomivosertib plus pembrolizumab or placebo plus pembrolizumab.

Key Points: 
  • This cohort will enroll approximately 60 patients, randomized 1:1 to initiate therapy with tomivosertib plus pembrolizumab or placebo plus pembrolizumab.
  • Revenue: Revenue was $0.3 million for the quarter ended December 31, 2021, compared to approximately $42 thousand for the same quarter of 2020.
  • General and Administrative (G&A) Expenses: G&A expenses were $6.3 million for the quarter ended December 31, 2021, compared to $1.1 million for the same quarter of 2020.
  • eFFECTOR cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Notice Concerning Application for Partial Revision of Manufacturing and Marketing Approval of Companion Diagnostic Reagent for the AmoyDx® Pan Lung Cancer PCR Panel

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, PCR, EGFR, Crizotinib, Growth, Chemotherapy, Gene, Polymerase chain reaction, ALK, BRAF, TRK, Mutation, Precision medicine, ROS1, Marketing, Patient, Technology, Organic acid, Partial, MET, Vaccine, NSCLC, Entrectinib

“We are pleased to announce this application. We look forward to getting marketing approval in order to help expand access to timely therapy options for Japanese patients,” stated representatives of the three companies -- Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis, Li-Mou Zheng, Ph.D., Founder and Chief Executive Officer of AmoyDx and Wenn Sun, Ph.D., Founder and President of PREMIA.

Key Points: 
  • The AmoyDx PLC Panel has received approval for five driver genes (EGFR, ALK, ROS1, BRAF, and MET exon 14 skipping), for ten associated, targeted therapies in NSCLC.
  • When ROS1 fusion genes are detected by the AmoyDx PLC Panel, it helps to determine the therapeutic indication for Crizotinib in patients with ROS1 fusion gene-positive NSCLC.
  • If the AmoyDx PLC Panel is approved for Entrectinib, it is expected to contribute to expanding treatment opportunities for patients with ROS1 fusion-positive NSCLC.
  • By inhibiting ROS1 and TRK kinase activity, Rozlytrek inhibits the growth of cancer cells with ROS1 or NTRK fusion genes.

Prostate Health Markets, 2026: Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Health, Oncology, CAGR, Patient, Chemotherapy, Man, Inflammation, Cancer vaccine, Pfizer, Prostate, Incidence, Prostate cancer, GlaxoSmithKline, Population, Growth, Tamsulosin, NA, Benign prostatic hyperplasia, BPH, OTC, Merck & Co., C1-inhibitor, USD, Risk, Male, Eli Lilly and Company, Medical imaging, Health insurance, Pharmaceutical industry, Prostatitis

The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate Hyperplasia (BPH), Tamsulosin, 5 Alpha Reductase, Prostatitis, OTC, Prescription (Rx), & Region (NA, Europe, APAC) - Global Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The three most common forms of prostate disease are inflammation (prostatitis), non-cancerous enlargement of the prostate (benign prostatic hyperplasia or BPH), and prostate cancer.
  • Based on disease indication, the prostate health market is segmented into prostate cancer, benign prostate hyperplasia, and prostatitis.
  • In 2020, prostate cancer accounted for the largest share in the prostate health market.